Gastric Inhibitory Polypeptide
"Gastric Inhibitory Polypeptide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A gastrointestinal peptide hormone of about 43-amino acids. It is found to be a potent stimulator of INSULIN secretion and a relatively poor inhibitor of GASTRIC ACID secretion.
| Descriptor ID |
D005749
|
| MeSH Number(s) |
D06.472.317.400 D06.472.699.275 D12.644.400.300 D12.644.548.275 D12.776.631.650.300
|
| Concept/Terms |
Gastric Inhibitory Polypeptide- Gastric Inhibitory Polypeptide
- Inhibitory Polypeptide, Gastric
- Polypeptide, Gastric Inhibitory
- Glucose-Dependent Insulin-Releasing Peptide
- Glucose Dependent Insulin Releasing Peptide
- Insulin-Releasing Peptide, Glucose-Dependent
- Peptide, Glucose-Dependent Insulin-Releasing
- Glucose Dependent Insulinotropic Peptide
- Glucose-Dependent Insulinotropic Peptide
- Insulinotropic Peptide, Glucose-Dependent
- Peptide, Glucose-Dependent Insulinotropic
- Gastric-Inhibitory Polypeptide
- Polypeptide, Gastric-Inhibitory
|
Below are MeSH descriptors whose meaning is more general than "Gastric Inhibitory Polypeptide".
Below are MeSH descriptors whose meaning is more specific than "Gastric Inhibitory Polypeptide".
This graph shows the total number of publications written about "Gastric Inhibitory Polypeptide" by people in this website by year, and whether "Gastric Inhibitory Polypeptide" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 1 | 1 |
| 2001 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2015 | 0 | 2 | 2 |
| 2016 | 0 | 2 | 2 |
| 2017 | 0 | 1 | 1 |
| 2020 | 1 | 1 | 2 |
| 2021 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
| 2025 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Gastric Inhibitory Polypeptide" by people in Profiles.
-
Compounded GLP-1 and Dual GIP/GLP-1 Receptor Agonists: A Statement from the American Diabetes Association. Diabetes Care. 2025 Feb 01; 48(2):177-181.
-
Dual Agonists for Management of Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2024 Jul 25; 391(4):371-372.
-
The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity. Diabetes. 2021 09; 70(9):1929-1937.
-
Gut Hormone GIP Induces Inflammation and Insulin Resistance in the Hypothalamus. Endocrinology. 2020 09 01; 161(9).
-
Metformin improves blood glucose by increasing incretins independent of changes in gluconeogenesis in youth with type 2 diabetes. Diabetologia. 2020 10; 63(10):2194-2204.
-
Metabolic hormones and breast cancer risk among Mexican American Women in the Mano a Mano Cohort Study. Sci Rep. 2019 07 10; 9(1):9989.
-
Brown adipose tissue is associated with systemic concentrations of peptides secreted from the gastrointestinal system and involved in appetite regulation. Eur J Endocrinol. 2017 Jul; 177(1):33-40.
-
Circulating cytokines as determinants of weight loss-induced improvements in insulin sensitivity. Endocrine. 2017 Jan; 55(1):153-164.
-
The Shape of the Glucose Response Curve During an Oral Glucose Tolerance Test Heralds Biomarkers of Type 2 Diabetes Risk in Obese Youth. Diabetes Care. 2016 Aug; 39(8):1431-9.
-
The effect of combined inositol supplementation on maternal metabolic profile in pregnancies complicated by?metabolic syndrome and obesity. Am J Obstet Gynecol. 2016 10; 215(4):503.e1-8.